1. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. (January 2020) Authors: Lind, M.; Gettinger, S.; Borghaei, H.; Brahmer, J.; Chow, L.; Burgio, M.; De Castro Carpeno, J.; Pluzanski, A.; Arrieta, O.; Frontera, O. Aren; Chiari, R.; Butts, C.; Wojcik-Tomaszewska, J.; Coudert, B.; Garassino, M.; Ready, N.; Felip, E.; Garcia, M. Alonso; Waterhouse, D.; Domine, M. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. (January 2020) Authors: Califano, R.; Camidge, D.; Kim, H.-R.; Ahn, M.-J.; Yang, J.; Han, J.-Y.; Hochmair, M.; Lee, K.H.; Delmonte, A.; Campelo, M.R. Garcia; Kim, D.-W.; Griesinger, F.; Felip, E.; Spira, A.; Gettinger, S.; Tiseo, M.; Ni, Q.; Zhang, P.; Popat, S. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes. (September 2015) Authors: Schmid, P.; Kowanetz, M.; Koeppen, H.; Zou, W.; Wistuba, I.; Kockx, M.; Kadel, E.E.; Chaft, J.; Rizvi, N.A.; Hirsch, F.R.; Smith, D.; Miley, N.; Leveque, V.; Shames, D.S.; Sandler, A.; Mellman, I.; Chen, D.S.; Hegde, P.S.; Gettinger, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. (October 2022) Authors: Reckamp, K.; Song, Z.; Gettinger, S.; Mitchell, E.P.; Wright, J.J.; Moscow, J.A.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.R.; Williams, P.M.; Hamilton, S.R.; Conley, B.A.; Arteaga, C.L.; Harris, L.N.; O'Dwyer, P.J.; Chen, A.P.; Flaherty, K.T. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. (December 2022) Authors: Gettinger, S.; Schenker, M.; De Langen, J.; Fischer, J.R.; Morgensztern, D.; Ciuleanu, T-E.; Beck, T.; De Castro Carpeno, J.; Schumann, C.; Yang, X.; Telivala, B.; Deschepper, K.; Nadal, E.; Schalper, K.; Spires, T.; Balli, D.; Nassar, A.; Karam, S.; Bhingare, A.; Spigel, D.R. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. (January 2019) Authors: Kim, D.; Huber, R.; Ahn, M.; Langer, C.; Tiseo, M.; West, H.; Groen, H.; Reckamp, K.; Hochmair, M.; Leighl, N.; Hansen, K.H.; Gettinger, S.; Paz-Ares Rodriguez, L.; Kim, E.; Smit, E.; Kim, S.; Reichmann, W.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗